Latest news
NewAmsterdam Pharma Wins CHMP Opinion for Obicetrapib Cholesterol Drug - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTNewAmsterdam reports $64.1M Q2 net loss, $678.3M cash; CHMP recommends obicetrapib approval - TradingViewTradingView · Wed, 05 Aug 2026 11:13:00 GMTPOSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE - AmgenAmgen · Wed, 29 Jul 2026 07:00:00 GMTNezglyal receives positive CHMP opinion supporting treatment access for boys with cALD - PharmaTimesPharmaTimes · Tue, 28 Jul 2026 10:03:00 GMT